Last updated: 2026-09-16 06:19:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Scribe Therapeutics Inc. (SCTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $31,73, with a market capitalization of $556,97M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17,31 to $39,60. This page covers its latest market performance, valuation, price trends and company information.
$556,97M | |
$30,19 | |
$39,60 | |
$17,31 | |
$29,42 | |
148,48K | |
237,76K | |
-- | |
$39,60 | |
$17,31 | |
-- | |
-- |
Scribe Therapeutics Inc. (SCTX) last closed at $29,42 as of 2026-09-15 23:35:00, unchanged from the previous close of $29,42.
During the latest regular trading session, SCTX traded between $17,31 and $39,60, with a volume of 148,48K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Scribe Therapeutics Inc. (SCTX) moved from $28,67 to $31,73, representing a gain of 10,67% ($3,06).
The stock traded between $27,61 and $32,16 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 164,62 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 64,7%
SCTX is currently trading at $31,73, placing it 64,7% of the way from its 52-week low of $17,31 to its 52-week high of $39,60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Scribe Therapeutics Inc. (SCTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.